Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Subscribe To Our Newsletter & Stay Updated
